EQUATOR-Oncology: reducing the latitude of cancer trial design and reporting

por Majeed, Habeeb, Amir, Eitan
Publicado 2018

Expedited approval of cancer drugs without randomized controlled trials: Too good to be true?

por Shepshelovich, Daniel, Amir, Eitan
Publicado 2018

Combining PARP inhibitors and platinum-based chemotherapy in metastatic triple negative and/or BRCA-associated breast cancer

por Molto Valiente, Consolacion, Amir, Eitan
Publicado 2023

HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer

por Barnes, Tristan A, Amir, Eitan
Publicado 2017

HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer

por Barnes, Tristan A, Amir, Eitan
Publicado 2018

Dual targeting of HER2-positive breast cancer with trastuzumab emtansine and pertuzumab: understanding clinical trial results

por Ocaña, Alberto, Amir, Eitan, Pandiella, Atanasio
Publicado 2018

HER2 heterogeneity and resistance to anti-HER2 antibody-drug conjugates

por Ocaña, Alberto, Amir, Eitan, Pandiella, Atanasio
Publicado 2020

Response to Soran et al.

por Reinhorn, Daniel, Amir, Eitan, Goldvaser, Hadar
Publicado 2021

Impact of comorbidity on the outcome in men with advanced prostate cancer treated with docetaxel

por Zist, Andrej, Amir, Eitan, Ocana, Alberto F., Seruga, Bostjan
Publicado 2015

Characteristics of Immune Checkpoint Inhibitors Trials Associated With Inclusion of Patients With HIV: A Systematic Review and Meta-analysis

por Sorotsky, Hadas, Hogg, David, Amir, Eitan, Araujo, Daniel V.
Publicado 2019

Are adjuvant bisphosphonates now standard of care of women with early stage breast cancer? A debate from the Canadian Bone and the Oncologist New Updates meeting

por Jacobs, Carmel, Amir, Eitan, Paterson, Alexander, Zhu, Xiaofu, Clemons, Mark
Publicado 2015

Bone-targeted therapy for metastatic breast cancer—Where do we go from here? A commentary from the BONUS 8 meeting

por Zhu, Xiaofu, Amir, Eitan, Singh, Gurmit, Clemons, Mark, Addison, Christina
Publicado 2014

Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis

por Ethier, Josee-Lyne, Desautels, Danielle, Templeton, Arnoud, Shah, Prakesh S., Amir, Eitan
Publicado 2017

Considerations for the clinical development of immuno-oncology agents in cancer

por Pandiella, Atanasio, Calvo, Emiliano, Moreno, Victor, Amir, Eitan, Templeton, Arnoud, Ocana, Alberto
Publicado 2023

Ubiquitin-conjugating enzyme E2T (UBE2T) and denticleless protein homolog (DTL) are linked to poor outcome in breast and lung cancers

por Perez-Peña, Javier, Corrales-Sánchez, Verónica, Amir, Eitan, Pandiella, Atanasio, Ocana, Alberto
Publicado 2017

Fragility of randomized trials supporting cancer drug approvals stratified by approval pathway and review designations

por Wilson, Brooke E., Desnoyers, Alexandra, Nadler, Michelle B., Tibau, Ariadna, Amir, Eitan
Publicado 2021

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis

por Reinhorn, Daniel, Mutai, Raz, Yerushalmi, Rinat, Moore, Assaf, Amir, Eitan, Goldvaser, Hadar
Publicado 2021

A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time

por Wilson, Brooke E., Desnoyers, Alexandra, Al-Showbaki, Laith, Nadler, Michelle B., Amir, Eitan
Publicado 2022

Efficacy and Safety of the Addition of Internal Mammary Irradiation to Standard Adjuvant Radiation in Early-Stage Breast Cancer: A Systematic Review and Meta-Analysis

por Korzets, Yasmin, Levitas, Dina, Grubstein, Ahuva, Corn, Benjamin W., Amir, Eitan, Goldvaser, Hadar
Publicado 2022

Cardiovascular Toxicity of Multi-Tyrosine Kinase Inhibitors in Advanced Solid Tumors: A Population-Based Observational Study

por Srikanthan, Amirrtha, Ethier, Josee-Lyne, Ocana, Alberto, Seruga, Bostjan, Krzyzanowska, Monika K., Amir, Eitan
Publicado 2015